Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more
Welcome Rocío Díaz, MD!
Texas Retina is pleased to welcome board-certified ophthalmologist and retina specialist Rocío Díaz, MD, to our practice on June 4, 2025. Serving patients in our Wichita Falls office, she will provide care
read more
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Happy New Year!
Happy New Year! Our offices will be closed on Wednesday, January 1, 2025. As another year comes to a close, we want to thank all of our patients, referring physicians, neighbors and
read more
Dr. Kothari Featured in New Retina Radio Podcast
Texas Retina’s Nikisha Kothari, MD, recently participated in a new podcast released by the New Retina Radio Journal Club and Vit-Buckle Society. In it, she discusses research published earlier this year in
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more
Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more
Monitoring Age-related Macular Degeneration at Home
As the leading cause of vision loss in older adults, age-related macular degeneration (AMD) is the most common reason patients are referred to Texas Retina. It happens when the central part of
read more